首页> 美国卫生研究院文献>Aging (Albany NY) >LINC00514 drives osteosarcoma progression through sponging microRNA-708 and consequently increases URGCP expression
【2h】

LINC00514 drives osteosarcoma progression through sponging microRNA-708 and consequently increases URGCP expression

机译:LINC00514通过海绵化microRNA-708驱动骨肉瘤进展并因此增加URGCP表达

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Long intergenic nonprotein-coding RNA 00514 (LINC00514) is upregulated in papillary thyroid cancer and contributes to its aggressiveness. In this study, we thoroughly explored the expression profile, specific functions, and relevant molecular mechanism of LINC00514 in osteosarcoma (OS). Herein, LINC00514 was significantly upregulated in OS tissues and cells, and increased LINC00514 expression was closely correlated with tumor size, TNM stage, and distant metastasis. OS patients with high LINC00514 expression had shorter overall survival than those with low LINC00514 expression. LINC00514 interference inhibited OS cell proliferation, colony formation, migration, and invasion but promoted cell apoptosis and G0/G1 cell cycle arrest. LINC00514 downregulation hindered OS tumor growth . Mechanistically, LINC00514 functioned as a competing endogenous RNA by directly interacting with microRNA-708-5p (miR-708) and consequently increasing the expression of upregulator of cell proliferation (URGCP). Both miR-708 knockdown and URGCP restoration partially neutralized anticancer activities of LINC00514 silencing in OS cells. LINC00514 increases URGCP expression by acting as a competing endogenous RNA for miR-708, thus exerting oncogenic roles in OS progression. In conclusion, the LINC00514/miR-708/URGCP pathway may be a promising target for drug discovery in the future.
机译:较长的基因间非蛋白质编码RNA 00514(LINC00514)在甲状腺乳头状癌中被上调,并对其侵略性有所贡献。在这项研究中,我们彻底探讨了LINC00514在骨肉瘤(OS)中的表达谱,特定功能和相关分子机制。在本文中,LINC00514在OS组织和细胞中显着上调,并且LINC00514表达的增加与肿瘤大小,TNM分期和远处转移密切相关。 LINC00514高表达的OS患者的总生存期比LINC00514低表达的OS患者短。 LINC00514干扰抑制OS细胞增殖,集落形成,迁移和侵袭,但促进细胞凋亡和G0 / G1细胞周期停滞。 LINC00514下调阻碍了OS肿瘤的生长。从机理上讲,LINC00514通过直接与microRNA-708-5p(miR-708)相互作用并因此增加细胞增殖上调剂(URGCP)的表达而充当竞争性内源RNA。 miR-708敲低和URGCP修复均部分抵消了OS细胞中LINC00514沉默的抗癌活性。 LINC00514通过充当miR-708的竞争内源RNA来增加URGCP表达,从而在OS进程中发挥致癌作用。总之,LINC00514 / miR-708 / URGCP途径可能是未来药物发现的有希望的目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号